Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency.
Sofia GronskayaZhanna BelayaLiudmila Ya RozhinskayaElizaveta MamedovaMaria V VorontsovaAlexander SolodovnikovOlga GolouninaGalina A MelnichenkoPublished in: Endocrine (2023)
Denosumab treatment was similarly effective at increasing BMD in patients with PHPT and PMO with and without renal insufficiency. The calcium lowering effects of denosumab were most significant in patients with PHPT and CKD. The safety of denosumab did not differ among participants with and without CKD.